地塞米松联合利妥昔单抗治疗成人免疫性血小板减少症疗效观察

Effect of dexamethasone combined with rituximabin therapy on adult primary immune thrombocytopenia

目的探讨地塞米松联合利妥昔单抗治疗成人原发性免疫性血小板减少症的临床疗效及安全性。方法 34例原发性免疫性血小板减少症成人患者,随机分为观察组16例和对照组18例,观察组给予地塞米松联合小剂量利妥昔单抗治疗,对照组给予大剂量地塞米松治疗,比较2组疗效和不良反应。结果观察组完全有效8例,部分有效5例,总有效率为81.25%;对照组完全有效7例,部分有效5例,总有效率为66.67%;观察组总有效率明显高于对照组(P<0.05);观察组不良反应发生率(18.75%)与对照组(16.67%)比较差异无统计学意义(P>0.05)。结论成人原发性免疫性血小板减少症患者应用地塞米松联合小剂量利妥昔单抗治疗有较高反应率,不良反应可耐受。

Objective To investigate the clinical efficacy and safety of dexamethasone combined with rituximabin therapy on adult primary immune thrombocytopenia. Methods Thirty-four adult patients with primary immune thrombocytopenia were randomly divided into observation group （n= 16） and control group （n=18）. Observation group was given dexamethasone combined with low-dose rituximabin therapy and control group was given high-dose dexamethasone therapy. The therapeutic effect and adverse reactions were recorded and compared between two groups. Results In observation group, 8 patients showed complete response and 5 showed partial response, with the overall response rate of 81. 25%. In control group, 7 patients showed completely response and 5 showed partial response, with the overall response rate of 66. 67%. The overall response rate was significantly higher in observation group than that in control group （P〈0.05）. There was no significant difference in the incidence of adverse reactions between observation group （18.75 % ） and control group （ 16.67 % ） （P〉 0.05）. Conclusion Dexamethasone combined with low-dose rituximabin has a striking therapeutic effect and the adverse reactions are tolerated.